Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Etanercept.

Costs of treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs in rheumatic diseases – data from the Romanian Registry of Rheumatic Diseases

Catalin Codreanu
Claudiu C. Popescu
Bogdan Baleanu
Corina Mogosan

March 2020

Given the limited resources of the health system, rheumatologists are interested in reducing the cos...

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice

Moots, R.J.
Haraoui, B.
Matucci-Cerinic, M.
Riel, P.L. van
Kekow, J.
Schaeverbeke, T.
Davis, A.
Tedeschi, M.A.
Freundlich, B.
Chang, D.J.
Singh, A.

January 2011

Item does not contain fulltextOBJECTIVES: To evaluate prevalence of dose escalation among RA patient...

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort.

Chevreul, Karine
Haour, Georges
Lucier, Sandy
Harvard, Stephanie
Laroche, Marie-Laure
Mariette, Xavier
Saraux, Alain
Durand-Zaleski, Isabelle
Guillemin, Francis
Fautrel, Bruno

January 2014

International audienceOBJECTIVES: To estimate annual direct costs of early RA by resource component ...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Adalimumab.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of second-line biologic agent-Rituximab.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis

Hyoungyoung Kim
Soo-Kyung Cho
Seongmi Choi
Seul Gi Im
Sun-Young Jung
Eun Jin Jang
Yoon-Kyoung Sung

June 2021

Objectives: To compare healthcare utilization and medical costs between patients with seronegative (...

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.

Griffiths, R
Bar-Din, M
MacLean, C
Sullivan, E
Herbert, R
Yelin, E

January 2001

We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving altern...

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D
Benucci M
Nappi C
Perrone V
Buda S
Degli Esposti L

November 2015

Diego Sangiorgi,1 Maurizio Benucci,2 Carmela Nappi,3 Valentina Perrone,1 Stefano Buda,1 Luca Degli E...

Economic consequences and potential benefits

Fautrel, Bruno
Verstappen, Suzanne M. M.
Boonen, Annelies

August 2011

Patients with established rheumatoid arthritis (RA) may incur important resource utilisation and wor...

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.

Griffiths, RI
Bar-Din, M
MacLean, CH
Sullivan, EM
Herbert, RJ
Yelin, EH

August 2000

OBJECTIVE: To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-...

Lapadula, G
Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

January 2012

Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted ...

Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?

Müskens, W.D.
Rongen-van Dartel, S.A.A.
Riel, P. van
Adang, E.M.

January 2021

Item does not contain fulltextOBJECTIVE: The market entry of biosimilars is expected to bring budget...

Cost-Effectiveness Analysis of Etanercept in Combination with Methotrexate for Rheumatoid Arthritis - Markov Model Based on Data from Serbia

Kostic Marina

December 2017

Biological therapeutic strategies have shown positive benefits for chronic and progressive rheumatoi...

Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.

Kuan-Chen Chen
Chu-Hua Wu
Chao-Hsiun Tang
Kuo-Cherh Huang

January 2018

OBJECTIVES:This nationwide population-based study aimed at evaluating healthcare resource utilizatio...

Costs of treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs in rheumatic diseases – data from the Romanian Registry of Rheumatic Diseases

Catalin Codreanu
Claudiu C. Popescu
Bogdan Baleanu
Corina Mogosan

March 2020

Given the limited resources of the health system, rheumatologists are interested in reducing the cos...

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice

Moots, R.J.
Haraoui, B.
Matucci-Cerinic, M.
Riel, P.L. van
Kekow, J.
Schaeverbeke, T.
Davis, A.
Tedeschi, M.A.
Freundlich, B.
Chang, D.J.
Singh, A.

January 2011

Item does not contain fulltextOBJECTIVES: To evaluate prevalence of dose escalation among RA patient...

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort.

Chevreul, Karine
Haour, Georges
Lucier, Sandy
Harvard, Stephanie
Laroche, Marie-Laure
Mariette, Xavier
Saraux, Alain
Durand-Zaleski, Isabelle
Guillemin, Francis
Fautrel, Bruno

January 2014

International audienceOBJECTIVES: To estimate annual direct costs of early RA by resource component ...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Adalimumab.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of second-line biologic agent-Rituximab.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis

Hyoungyoung Kim
Soo-Kyung Cho
Seongmi Choi
Seul Gi Im
Sun-Young Jung
Eun Jin Jang
Yoon-Kyoung Sung

June 2021

Objectives: To compare healthcare utilization and medical costs between patients with seronegative (...

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.

Griffiths, R
Bar-Din, M
MacLean, C
Sullivan, E
Herbert, R
Yelin, E

January 2001

We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving altern...

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D
Benucci M
Nappi C
Perrone V
Buda S
Degli Esposti L

November 2015

Diego Sangiorgi,1 Maurizio Benucci,2 Carmela Nappi,3 Valentina Perrone,1 Stefano Buda,1 Luca Degli E...

Economic consequences and potential benefits

Fautrel, Bruno
Verstappen, Suzanne M. M.
Boonen, Annelies

August 2011

Patients with established rheumatoid arthritis (RA) may incur important resource utilisation and wor...

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.

Griffiths, RI
Bar-Din, M
MacLean, CH
Sullivan, EM
Herbert, RJ
Yelin, EH

August 2000

OBJECTIVE: To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-...

Lapadula, G
Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

January 2012

Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted ...

Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve?

Müskens, W.D.
Rongen-van Dartel, S.A.A.
Riel, P. van
Adang, E.M.

January 2021

Item does not contain fulltextOBJECTIVE: The market entry of biosimilars is expected to bring budget...

Cost-Effectiveness Analysis of Etanercept in Combination with Methotrexate for Rheumatoid Arthritis - Markov Model Based on Data from Serbia

Kostic Marina

December 2017

Biological therapeutic strategies have shown positive benefits for chronic and progressive rheumatoi...

Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.

Kuan-Chen Chen
Chu-Hua Wu
Chao-Hsiun Tang
Kuo-Cherh Huang

January 2018

OBJECTIVES:This nationwide population-based study aimed at evaluating healthcare resource utilizatio...

Costs of treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs in rheumatic diseases – data from the Romanian Registry of Rheumatic Diseases

Catalin Codreanu
Claudiu C. Popescu
Bogdan Baleanu
Corina Mogosan

March 2020

Given the limited resources of the health system, rheumatologists are interested in reducing the cos...

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice

Moots, R.J.
Haraoui, B.
Matucci-Cerinic, M.
Riel, P.L. van
Kekow, J.
Schaeverbeke, T.
Davis, A.
Tedeschi, M.A.
Freundlich, B.
Chang, D.J.
Singh, A.

January 2011

Item does not contain fulltextOBJECTIVES: To evaluate prevalence of dose escalation among RA patient...

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort.

Chevreul, Karine
Haour, Georges
Lucier, Sandy
Harvard, Stephanie
Laroche, Marie-Laure
Mariette, Xavier
Saraux, Alain
Durand-Zaleski, Isabelle
Guillemin, Francis
Fautrel, Bruno

January 2014

International audienceOBJECTIVES: To estimate annual direct costs of early RA by resource component ...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Etanercept.

Abstract

Extracted data

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Etanercept.

Abstract

Extracted data

Related items

Related items